NEW YORK, March 29 – Packard Biosciences has indefinitely postponed a planned follow-on offering of 10 million shares of its common stock, the company said Thursday.

The offering, which the company had announced in early February, is being postponed due to the downturn in the market, said Mike Zebarth, a company spokesman. Packard has filed an amended registration with the US Securities and Exchange Commission to reflect the change of plans.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.